In other tumor types, serglycin has been confirmed to promote metastatic tumor growth, and in vitro observations of human glioma tumor cells have shown increased release of the glioma stem cell marker CD44 mediated by serglycin. The gene discussed is SRGN; the disease is neoplasm.